Influence of the American ODAC statement on Austrian bevacizumab prescribing practice for metastatic breast cancer.

Matthias Preusser; Gerhard Fülöp; Anna Sophie Berghoff; Harald Heinzl; Guenther G Steger; Richard Greil; Christoph C Zielinski; Rupert Bartsch

doi:10.1634/theoncologist.2012-0115

Influence of the American ODAC statement on Austrian bevacizumab prescribing practice for metastatic breast cancer.

Matthias Preusser
, Gerhard Fülöp
, Anna Sophie Berghoff
, Harald Heinzl
, Guenther G Steger
, Richard Greil (Co-Autor/-in)
, Christoph C Zielinski
, Rupert Bartsch

Universitätsklinik für Innere Medizin 3 - Hämatologie, internistische Onkologie, Hämostaseologie, Infektiologie, Rheumatologie und Onkologisches Zentrum

Publikation: Beitrag in Fachzeitschrift › Originalarbeit › Begutachtung

7 Quellenangaben (Web of Science)

Originalsprache	Englisch
Seiten (von - bis)	e13-e17
Fachzeitschrift	ONCOLOGIST
Jahrgang	17
Ausgabenummer	7
DOIs	https://doi.org/10.1634/theoncologist.2012-0115
Publikationsstatus	Veröffentlicht - 2012

Zugriff auf Dokument

10.1634/theoncologist.2012-0115

Dieses zitieren

@article{14bdab02a3764ca8a42115303de59d71,

title = "Influence of the American ODAC statement on Austrian bevacizumab prescribing practice for metastatic breast cancer.",

keywords = "PHASE-III TRIAL, NEOADJUVANT CHEMOTHERAPY",

author = "Matthias Preusser and Gerhard F{\"u}l{\"o}p and Berghoff, \{Anna Sophie\} and Harald Heinzl and Steger, \{Guenther G\} and Richard Greil and Zielinski, \{Christoph C\} and Rupert Bartsch",

year = "2012",

doi = "10.1634/theoncologist.2012-0115",

language = "English",

volume = "17",

pages = "e13--e17",

journal = "ONCOLOGIST",

issn = "1083-7159",

number = "7",

}

TY - JOUR

T1 - Influence of the American ODAC statement on Austrian bevacizumab prescribing practice for metastatic breast cancer.

AU - Preusser, Matthias

AU - Fülöp, Gerhard

AU - Berghoff, Anna Sophie

AU - Heinzl, Harald

AU - Steger, Guenther G

AU - Greil, Richard

AU - Zielinski, Christoph C

AU - Bartsch, Rupert

PY - 2012

Y1 - 2012

KW - PHASE-III TRIAL

KW - NEOADJUVANT CHEMOTHERAPY

U2 - 10.1634/theoncologist.2012-0115

DO - 10.1634/theoncologist.2012-0115

M3 - Original Article

C2 - 22744818

SN - 1083-7159

VL - 17

SP - e13-e17

JO - ONCOLOGIST

JF - ONCOLOGIST

IS - 7

ER -